The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated
inflammatory bowel disease (IBD) treatment and increased medical costs. The recent …

Background: Several adalimumab preparations are now available for patients with
inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown …

Markers that allow for the selection of tailored treatments for individual patients with
inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in …

Introduction Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but
previously expensive biological treatment for psoriasis. The introduction of biosimilars …

Adalimumab biosimilar experience is still recent. Interchangeability differences could reduce
persistence times. Our goal was to compare biosimilar persistence differences with a …

Background The lack of evidence under routine clinical settings limited the widespread
adoption of adalimumab biosimilars for psoriasis treatment. Objective This study compared …

BACKGROUND Over the last decade, the treatment options for inflammatory bowel disease
(IBD) have significantly progressed with the emergence of new medications designed to …

目的: 系统评价阿达木单抗生物类似药临床互换用药的有效性, 安全性与免疫原性,
为临床互换用药提供循证参考. 方法: 系统检索Pubmed, Embase, Cochrane Library, CNKI …

Annual out-of-pocket expenditures for patients with inflammatory bowel disease (IBD) are
estimated to be as high as $41,000, with medications, such as biologics, being one of the …

AIM: To systematically evaluate the clinical interchangeability of adalimumab biosimilars in
terms of efficacy, safety, and immunogenicity, and to provide evidence-based reference for …